FAS-670 A>G基因多态性与宫颈癌发病风险的meta分析  

FAS-670 A > G Polymorphism and Risk of Cervical Cancer: a Meta-Analysis

作　　者：杨云[1] 李松柏[1] 张细梅[2] 廖兵荣[1] 张映 YANG Yun1, LI Song- bo1, ZHANG Xi -mei2, LIAO Bing- tong1, ZHANG Ying3(1. Medical School of Yichun University, Institute of Preventive Medicine of Yichun University, Yichun 336000, 2. Department of Nephrology in Jiangxi People＇s Hospital, Nanchang 330006, China; 3. Cixi Kandun Hospital, Cixi 315303, China)

机构地区：[1]宜春学院医学院宜春学院预防医学研究所,江西宜春336000 [2]江西省人民医院肾内科,南昌330006 [3]慈溪市坎墩医院,浙江慈溪315303

出　　处：《宜春学院学报》2018年第9期56-62,共7页Journal of Yichun University

摘　　要：目的:探讨FAS-670 A> G基因多态性与宫颈癌发病风险的关联。方法:于Pubmed、知网等数据库中全面检索相关文献,收集2016年12月前公开发表的相关文献,使用Stata12. 0进行meta分析。结果:经过严格标准筛选,最终纳入本次meta分析的研究共13项,累计病例3146例,对照3070例。共记录4种模式:纯合子(GG vs AA);显性模式(AG+GG vs AA);隐性模式(GG vs AA+AG);等位基因(G vs A)。在各模式中,meta分析的OR值及95%置信区间分别为1. 00 (0. 78-1. 28); 1. 05 (0. 84-1. 32); 1. 02 (0. 84-1. 25); 1. 02(0. 91-1. 15),且按种族进行亚组分析中各OR值均无统计学意义。结论:FAS-670 A> G基因多态性与宫颈癌发病风险之间无显著性关联。Objective： In order to Explore the association between FAS -670 A 〉 G polymorphism and the risk of cervical cancer. Methods： the relevant articles published before December 2016 was retrieved from the database of Pubmed and CNKI, and the meta analysis was carried out by Stata 12.0. Results： Thirteen studies, which contended 3146 cases and 3070 controls in total, were finally selected through executing rigid standards. By considering the wild type genotype （AA） or allele （A） as the reference, the ORs and 95 % CIs were calculated separately for 4 genetic models ： homozygous （ GG vs AA）, dominant （ AG ＋ GG vs AA）, recessive model （ GG vs AA ＋ AG） and allele contrast （ G vs A） . In overall meta - analysis, the pooled Ors and their 95% confidence interals were 1.00 （0.78-1.28）; 1.05 （0.84-1.32）; 1.02 （0.84-1.25）; 1.02 （0.91-1.15） .Alsowith the subgroup analysis, there are no significant differences in all models. Conclusion ： The FAS - 670 A 〉 G polymorphism might not contribute to the susceptibility of cervical cancer.

关 键 词：FAS 宫颈癌 基因多态性 META分析 

分 类 号：R737.33[医药卫生—肿瘤]